Finally, we used multiple drug effect/combination index (CI) isobologram analysis to study the efficacy of chemotherapeutic drugs plus lapatinib combinations tested against lapatinib-sensitive HER2-amplified/overexpressing or EGFR-expressing endometrial cancer cells. This evidence concerns the gene ERBB2 and endometrial cancer.